Hikma Pharmaceuticals Stock Price, News & Analysis (LON:HIK)

GBX 982 -13.00 (-1.31 %)
(As of 01/21/2018 04:00 PM ET)
Previous CloseGBX 982
Today's RangeGBX 981.80 - GBX 1,005
52-Week RangeGBX 906.50 - GBX 2,346
Volume639,895 shs
Average Volume586,474 shs
Market Capitalization£2.37 billion
P/E Ratio1,964.00
Dividend YieldN/A
BetaN/A

About Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals logoHikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The Company sells specialized generic injectable products across the globe. It also sells non-injectable generic products in the United States, supplying over 260 products in approximately 110 different dosage strengths and forms. The Company's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Receive HIK News and Ratings via Email

Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolLON:HIK
CUSIPN/A
Phone+44-20-73992760

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio1964
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX 0.50
Net IncomeN/A
Net Margins7.82%
Return on Equity5.69%
Return on Assets3.19%

Miscellaneous

EmployeesN/A
Outstanding Shares240,660,000

Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Wednesday, March 15th. Stockholders of record on Thursday, April 6th will be given a dividend of GBX 0.22 per share on Thursday, May 25th. This represents a dividend yield of 0.78%. The ex-dividend date of this dividend is Thursday, April 6th. This is a positive change from Hikma Pharmaceuticals's previous dividend of $0.21. The official announcement can be viewed at this link. View Hikma Pharmaceuticals' Dividend History.

Where is Hikma Pharmaceuticals' stock going? Where will Hikma Pharmaceuticals' stock price be in 2018?

9 Wall Street analysts have issued 1 year price objectives for Hikma Pharmaceuticals' stock. Their predictions range from GBX 895 to GBX 1,500. On average, they expect Hikma Pharmaceuticals' share price to reach GBX 1,205 in the next twelve months. View Analyst Ratings for Hikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:

  • Said Darwazah, Chairman of the Board, Chief Executive (Age 59)
  • Mazen Samih Talib Darwazah, Executive Vice Chairman of the Board, President and Chief Executive Officer of MENA and Emerging Markets (Age 58)
  • Khalid Nabilsi, Chief Financial Officer
  • Brian Hoffman, President, West-Ward Pharmaceuticals
  • Michael Raya, Chief Executive Officer, West-Ward Pharmaceuticals
  • Majda Labadi, Corporate Vice President - Human Resources and Head of Operations, MENA
  • Riad Mishlawi, EU Vice President and Global Head - Injectables
  • Susan Ringdal, Vice President - Corporate Strategy and Investor Relations
  • Hussein Arkhagha, General Counsel
  • Bassam Wael Rushdi Kanaan, Chief Strategy and Corporate Development Officer (Age 51)

How do I buy Hikma Pharmaceuticals stock?

Shares of Hikma Pharmaceuticals and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Hikma Pharmaceuticals' stock price today?

One share of Hikma Pharmaceuticals stock can currently be purchased for approximately GBX 982.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of £2.37 billion.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760.


MarketBeat Community Rating for Hikma Pharmaceuticals (HIK)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  416 (Vote Outperform)
Underperform Votes:  218 (Vote Underperform)
Total Votes:  634
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Hikma Pharmaceuticals (LON:HIK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.112.222.202.44
Ratings Breakdown: 1 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 1,205GBX 1,224.89GBX 1,526.60GBX 2,017.89

Hikma Pharmaceuticals (LON:HIK) Consensus Price Target History

Price Target History for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON:HIK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/17/2018Jefferies GroupReiterated RatingUnderperformGBX 895View Rating Details
1/15/2018JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
12/20/2017Numis SecuritiesReiterated RatingBuyGBX 1,300View Rating Details
12/1/2017Morgan StanleyReiterated RatingEqual weightGBX 1,100View Rating Details
11/15/2017Peel HuntReiterated RatingHoldGBX 1,390View Rating Details
11/9/2017Stifel NicolausLower Price TargetHoldGBX 1,320 -> GBX 1,000View Rating Details
8/25/2017BarclaysLower Price TargetOverweightGBX 2,200 -> GBX 1,500View Rating Details
8/24/2017CitigroupReiterated RatingNeutralGBX 1,350View Rating Details
8/22/2017Goldman Sachs GroupDowngradeNeutralGBX 2,600 -> GBX 1,310View Rating Details
11/30/2016AlphaValueReiterated RatingBuyGBX 2,431View Rating Details
3/16/2016Panmure GordonUpgradeBuyGBX 2,120View Rating Details
(Data available from 1/21/2016 forward)

Earnings

Earnings History for Hikma Pharmaceuticals (LON:HIK)


No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Hikma Pharmaceuticals (LON:HIK) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Hikma Pharmaceuticals (LON:HIK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/15/2017€0.220.78%4/6/20174/6/20175/25/2017
3/11/2015€0.210.64%4/16/20154/16/20155/21/2015
(Data available from 1/1/2013 forward)

Insider Trades

Hikma Pharmaceuticals (LON HIK) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Hikma Pharmaceuticals (LON:HIK)

Hikma Pharmaceuticals (LON HIK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/19/2016Ali Al-HusryInsiderBuy50,000GBX 1,790£895,000
12/16/2016Mazen DarwazahInsiderBuy90,730GBX 1,849£1,677,597.70
12/12/2016Ali Al-HusryInsiderBuy50,000GBX 1,707£853,500
12/9/2016Ali Al-HusryInsiderBuy50,000GBX 1,723£861,500
12/6/2016Ali Al-HusryInsiderBuy100,000GBX 1,682£1,682,000
12/5/2016Ali Al-HusryInsiderBuy50,000GBX 1,674£837,000
12/2/2016Mazen DarwazahInsiderBuy50,000GBX 1,662£831,000
12/1/2016Mazen DarwazahInsiderBuy50,000GBX 1,674£837,000
11/30/2016Said DarwazahInsiderBuy50,000GBX 1,662£831,000
9/28/2016Said DarwazahInsiderBuy10,000GBX 2,085£208,500
9/27/2016Ali Al-HusryInsiderBuy50,000GBX 2,094£1,047,000
9/26/2016Said DarwazahInsiderBuy50,000GBX 2,078£1,039,000
9/23/2016Ali Al-HusryInsiderBuy50,000GBX 2,099£1,049,500
9/21/2016Ali Al-HusryInsiderBuy50,000GBX 2,138£1,069,000
9/16/2016Al-Husry,AliInsiderBuy50,000GBX 2,119£1,059,500
9/15/2016Darwazah,SaidInsiderBuy70,251GBX 2,122£1,490,726.22
9/8/2016Darwazah,MazenInsiderBuy150,000GBX 2,162£3,243,000
9/6/2016Darwazah,MazenInsiderBuy155,991GBX 2,194£3,422,442.54
8/31/2016Al-Husry,AliInsiderBuy140,000GBX 2,150£3,010,000
8/26/2016Darwazah,SaidInsiderBuy200,000GBX 2,160£4,320,000
6/24/2016Darwazah,MazenInsiderBuy150,000GBX 2,200£3,300,000
6/17/2016Al-Husry,AliInsiderBuy70,000GBX 22£15,400
5/9/2016Darwazah,SaidInsiderBuy17,440GBX 2,228£388,563.20
4/26/2016Darwazah,SaidInsiderBuy10,000GBX 2,260£226,000
4/25/2016Darwazah,SaidInsiderBuy10,000GBX 2,324£232,400
4/22/2016Darwazah,SaidInsiderBuy30,000GBX 2,325£697,500
4/20/2016Darwazah,SaidInsiderBuy30,000GBX 2,271£681,300
4/19/2016Darwazah,SaidInsiderBuy30,000GBX 2,266£679,800
4/11/2016J. Castellani,JohnInsiderBuy2,500GBX 2,103£52,575
4/7/2016Darwazah,MazenInsiderBuy60,000GBX 2,118£1,270,800
4/5/2016Darwazah,SaidInsiderBuy30,000GBX 2,055£616,500
3/31/2016Darwazah,SaidInsiderBuy30,000GBX 1,972£591,600
3/24/2016Butler,PatInsiderBuy2,500GBX 1,920£48,000
3/21/2016Pickering ,RobertInsiderBuy2,500GBX 1,856£46,400
8/27/2015Kirby,PamelaInsiderBuy3,317GBX 2,264£75,096.88
(Data available from 1/1/2013 forward)

Headlines

Hikma Pharmaceuticals (LON HIK) News Headlines

Source:
DateHeadline
Hikma Pharmaceuticals Plc (HIK) Receives Average Rating of "Hold" from AnalystsHikma Pharmaceuticals Plc (HIK) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 19 at 6:26 AM
Deutsche Bank Reduces Stake In Hikma Pharmaceuticals (ALLISS)Deutsche Bank Reduces Stake In Hikma Pharmaceuticals (ALLISS)
www.morningstar.co.uk - January 17 at 3:44 PM
Drugmaker Dermapharm gears up for likely first German IPO of 2018Drugmaker Dermapharm gears up for likely first German IPO of 2018
finance.yahoo.com - January 15 at 3:44 PM
JPMorgan Chase & Co. Reaffirms Neutral Rating for Hikma Pharmaceuticals (HIK)JPMorgan Chase & Co. Reaffirms Neutral Rating for Hikma Pharmaceuticals (HIK)
www.americanbankingnews.com - January 15 at 11:52 AM
Hikma Pharmaceuticals (HIK) Price Target Raised to GBX 1,074 at Jefferies GroupHikma Pharmaceuticals (HIK) Price Target Raised to GBX 1,074 at Jefferies Group
www.americanbankingnews.com - December 25 at 10:54 PM
Hikma Pharmaceuticals Plc (HIK) Given Consensus Recommendation of "Hold" by BrokeragesHikma Pharmaceuticals Plc (HIK) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - December 25 at 5:44 AM
Numis Securities Reiterates Buy Rating for Hikma Pharmaceuticals (HIK)Numis Securities Reiterates Buy Rating for Hikma Pharmaceuticals (HIK)
www.americanbankingnews.com - December 23 at 9:14 PM
Hikma wins right to market Roche drug copy in Middle East and North Africa - ReutersHikma wins right to market Roche drug copy in Middle East and North Africa - Reuters
www.reuters.com - December 20 at 11:21 AM
Hikma Pharmaceuticals Plc – Value Analysis (LONDON:HIK) : December 19, 2017Hikma Pharmaceuticals Plc – Value Analysis (LONDON:HIK) : December 19, 2017
finance.yahoo.com - December 19 at 3:43 PM
Hikma Pharma Unit Launches Dihydroergotamine Mesylate Injection In US - NasdaqHikma Pharma Unit Launches Dihydroergotamine Mesylate Injection In US - Nasdaq
www.nasdaq.com - December 13 at 3:48 PM
ETFs with exposure to Hikma Pharmaceuticals Plc : December 13, 2017ETFs with exposure to Hikma Pharmaceuticals Plc : December 13, 2017
finance.yahoo.com - December 13 at 3:48 PM
Hikma Pharmaceuticals Launches Migraine Treatment Injection In USHikma Pharmaceuticals Launches Migraine Treatment Injection In US
www.morningstar.co.uk - December 13 at 11:38 AM
Hikma launches injectable treatment for headachesHikma launches injectable treatment for headaches
www.marketwatch.com - December 13 at 11:38 AM
BRIEF-Hikma Says Hikma Ventures Has Participated In Financing For PrognosBRIEF-Hikma Says Hikma Ventures Has Participated In Financing For Prognos
www.reuters.com - December 1 at 6:27 PM
Hikma Pharmaceuticals (HIK) Stock Rating Reaffirmed by Morgan StanleyHikma Pharmaceuticals (HIK) Stock Rating Reaffirmed by Morgan Stanley
www.americanbankingnews.com - December 1 at 6:12 AM
Hikma Pharmaceuticals PLC (HIK) Given Average Rating of "Hold" by BrokeragesHikma Pharmaceuticals PLC (HIK) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 30 at 6:28 AM
BRIEF-Hikma Pharmaceuticals ‍invests in biosensor tech firm BiolinqBRIEF-Hikma Pharmaceuticals ‍invests in biosensor tech firm Biolinq
www.reuters.com - November 27 at 5:32 PM
Hikma Pharmaceuticals Invests In Digital Health Firm BiolinqHikma Pharmaceuticals Invests In Digital Health Firm Biolinq
www.morningstar.co.uk - November 27 at 5:32 PM
Hikma Pharmaceuticals PLCs (HIK) Hold Rating Reiterated at Peel HuntHikma Pharmaceuticals PLC's (HIK) Hold Rating Reiterated at Peel Hunt
www.americanbankingnews.com - November 25 at 10:10 AM
Hikma buys 6 Boehringer products in $3.5 mln deal - MarketWatchHikma buys 6 Boehringer products in $3.5 mln deal - MarketWatch
www.marketwatch.com - November 16 at 9:40 PM
Hikma buys 6 Boehringer products in $3.5 mln dealHikma buys 6 Boehringer products in $3.5 mln deal
www.marketwatch.com - November 14 at 5:33 AM
West-Ward Columbus taking on pill manufacturing from New Jersey sister plantWest-Ward Columbus taking on pill manufacturing from New Jersey sister plant
www.bizjournals.com - November 13 at 7:29 PM
Hikma Pharmaceuticals Plc (HIK) PT Lowered to GBX 1,000 at J P Morgan Chase & CoHikma Pharmaceuticals Plc (HIK) PT Lowered to GBX 1,000 at J P Morgan Chase & Co
www.americanbankingnews.com - November 12 at 8:34 PM
Numis Securities Ltd Upgrades Hikma Pharmaceuticals Plc (HIK) to BuyNumis Securities Ltd Upgrades Hikma Pharmaceuticals Plc (HIK) to Buy
www.americanbankingnews.com - November 9 at 7:58 AM
Hikma Pharmaceuticals Plc (HIK) PT Lowered to GBX 1,000Hikma Pharmaceuticals Plc (HIK) PT Lowered to GBX 1,000
www.americanbankingnews.com - November 9 at 7:58 AM
TOP NEWS: Hikma Cuts View, Pursues Dispute With FDA On Generic AdvairTOP NEWS: Hikma Cuts View, Pursues Dispute With FDA On Generic Advair
www.morningstar.co.uk - November 9 at 6:40 AM
Hikma cuts guidance on generics unit for 3rd timeHikma cuts guidance on generics unit for 3rd time
www.marketwatch.com - November 9 at 6:40 AM
Hikma Pharma Backs FY17 Revenue View, Cuts Forecast For Generics; Stock DownHikma Pharma Backs FY17 Revenue View, Cuts Forecast For Generics; Stock Down
www.rttnews.com - November 9 at 6:40 AM
UPDATE 1-UK Stocks-Factors to watch on Nov 9 - ReutersUPDATE 1-UK Stocks-Factors to watch on Nov 9 - Reuters
www.reuters.com - November 9 at 6:39 AM
UPDATE 1-Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again - ReutersUPDATE 1-Hikma in dispute with FDA over generic Advair, cuts generics sales forecast again - Reuters
www.reuters.com - November 9 at 6:39 AM
FTSE under pressure as Burberry revamps its strategyFTSE under pressure as Burberry revamps its strategy
finance.yahoo.com - November 9 at 6:39 AM
Hikma Pharmaceuticals Plc (HIK) Given Consensus Recommendation of "Hold" by AnalystsHikma Pharmaceuticals Plc (HIK) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 5 at 6:22 AM
Hikma Pharmaceuticals Launches Flucytosine Capsules In USHikma Pharmaceuticals Launches Flucytosine Capsules In US
www.morningstar.co.uk - November 4 at 4:41 AM
Hikma US unit launches heartburn drug - MarketWatchHikma US unit launches heartburn drug - MarketWatch
www.marketwatch.com - November 2 at 12:13 AM
Why Hikma Pharmaceuticals PLC’s (LSE:HIK) ROE Of 6.97% Does Not Tell The Whole StoryWhy Hikma Pharmaceuticals PLC’s (LSE:HIK) ROE Of 6.97% Does Not Tell The Whole Story
finance.yahoo.com - November 2 at 12:13 AM
Why I’d buy this FTSE 250 stock alongside AstraZeneca plcWhy I’d buy this FTSE 250 stock alongside AstraZeneca plc
www.fool.co.uk - October 30 at 3:33 PM
Hikma U.S. unit launches heartburn drugHikma U.S. unit launches heartburn drug
www.marketwatch.com - October 30 at 3:33 PM
BRIEF-Hikma says US unit launched pantoprazole sodium for injectionBRIEF-Hikma says US unit launched pantoprazole sodium for injection
www.reuters.com - October 30 at 3:33 PM
Hikma Pharmaceuticals Plc – Value Analysis (LONDON:HIK) : October 25, 2017Hikma Pharmaceuticals Plc – Value Analysis (LONDON:HIK) : October 25, 2017
finance.yahoo.com - October 26 at 10:51 AM
Hikma Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : HIK-GB : October 24, 2017Hikma Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : HIK-GB : October 24, 2017
finance.yahoo.com - October 25 at 3:39 AM
Have Investors Already Priced In Hikma Pharmaceuticals PLC’s (LSE:HIK) Growth?Have Investors Already Priced In Hikma Pharmaceuticals PLC’s (LSE:HIK) Growth?
finance.yahoo.com - October 19 at 2:07 AM
ETFs with exposure to Hikma Pharmaceuticals Plc : October 17, 2017ETFs with exposure to Hikma Pharmaceuticals Plc : October 17, 2017
finance.yahoo.com - October 17 at 8:09 PM
Hikma Pharmaceuticals Plc (HIK) Given Consensus Rating of "Hold" by AnalystsHikma Pharmaceuticals Plc (HIK) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - October 11 at 6:28 AM
Hikma Pharmaceuticals Plc (HIK) Price Target Lowered to GBX 1,250 at J P Morgan Chase & CoHikma Pharmaceuticals Plc (HIK) Price Target Lowered to GBX 1,250 at J P Morgan Chase & Co
www.americanbankingnews.com - October 7 at 8:02 PM
Should You Be Tempted To Buy Hikma Pharmaceuticals PLC (LSE:HIK) Because Of Its PE Ratio?Should You Be Tempted To Buy Hikma Pharmaceuticals PLC (LSE:HIK) Because Of Its PE Ratio?
finance.yahoo.com - October 3 at 9:45 AM
Hikma Pharmaceuticals Plc (HIK) Stock Rating Reaffirmed by J P Morgan Chase & CoHikma Pharmaceuticals Plc (HIK) Stock Rating Reaffirmed by J P Morgan Chase & Co
www.americanbankingnews.com - September 29 at 8:34 PM
EXTRA: Vectura Posts Pretax Loss Increase Due To Amortisation CostsEXTRA: Vectura Posts Pretax Loss Increase Due To Amortisation Costs
www.morningstar.co.uk - September 6 at 7:23 PM
ETFs with exposure to Hikma Pharmaceuticals Plc : August 29, 2017ETFs with exposure to Hikma Pharmaceuticals Plc : August 29, 2017
finance.yahoo.com - August 29 at 8:00 PM
Hikma Pharmaceuticals Plc (HIK) Downgraded by Stifel NicolausHikma Pharmaceuticals Plc (HIK) Downgraded by Stifel Nicolaus
www.americanbankingnews.com - August 29 at 6:38 AM
Hikma Pharmaceuticals Plcs (HIK) "Neutral" Rating Reaffirmed at Citigroup Inc.Hikma Pharmaceuticals Plc's (HIK) "Neutral" Rating Reaffirmed at Citigroup Inc.
www.americanbankingnews.com - August 28 at 12:56 AM

SEC Filings

Hikma Pharmaceuticals (LON:HIK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

Hikma Pharmaceuticals (LON HIK) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.